🎓✨ Honoured to be appointed Associate Professor in Rheumatology at @chulille.bsky.social @ufr3s-ulille.bsky.social 🙏 Grateful to keep caring for patients, advancing research in chronic inflammatory diseases (esp. spondyloarthritis) & teaching future clinicians. Thanks to all who supported me!

🎓 Congratulations to Astrid Goudot for her outstanding medical thesis defence in both 🇫🇷🇬🇧 on predictive factors of D2T PsA in patients initiating their 1st bDMARD. 👏👏 Many thanks to Laura Coates who shared her valuable expertise on this timely topic 🌍👏

🧪 Late-breaking APEX trial results! In active PsA pts (≥3 TJC/SJC, CRP ≥0.3, erosions on X-ray), GUS Q4W & Q8W 🆚 PBO showed: 🦴 Less radiographic progression at W24 (vdH-S: 0.55/0.54 vs 1.35; P=0.002/<0.001) 💪 Higher ACR20 responses #EULAR2025 Posted by @jgletarouilly.bsky.social

🧬 Does MTX with 1st ADA shot prevent anti-ADA antibodies in axSpA? 🇫🇷 MESYNAD RCT: ❌ No difference at 6mo 💉 MTX+ADA = ADA alone No added benefit for immunogenicity. #EULAR2025 #POS0889 Posted by @jgletarouilly.bsky.social

Gaslighting and Unconscious Bias in Rheumatology , a powerful session at #EULAR2025 exposing the harm caused within and beyond clinical teams. Disagree Well. Speak truth. Challenge bias. #Gaslighting #UnconsciousBias #EULAR2025 IH

📲 Inspiring work from Deniz Bayraktar at #EULAR2025! She adapted the SARAH self-rehab programme for people with RA in Türkiye — and delivered it via WhatsApp! 🇹🇷💬 A brilliant example of accessible care in action.

📊 RABBIT-SpA registry insights: 🔹 8.5% met ASAS D2M axSpA criteria (75/881) 🔹 2.5% met TR criteria (22/881) 👩 D2M-axSpA patients = more female, less HLA-B27 Results similar to those from the Dutch cohort #EULAR2025 Posted by @jgletarouilly.bsky.social

🧠✨GRAPPA Definitions 🔹Complex-to-Manage PsA (C2M PsA) ➡️ Persistent symptoms despite treatment with≥1 b/tsDMARD 💊 🔸 Difficult-to-Treat PsA (D2T PsA) ➡️ Characterized by failure to respond to ≥3 prior PsA therapies with different MoA 🔄💥 #EULAR2025 Posted by @jgletarouilly.bsky.social

🔬SPEED RCT in patients with PsA and poor prognostic factors 🎯 Primary Endpoint: Mean PASDAS at 24 weeks ✅ Combination csDMARDs** > Standard step-up ✅️TNFi** > Standard step-up ❌ No significant difference between Combination csDMARDs and TNFi #EULAR2025 Posted by @jgletarouilly.bsky.social

🌟Thrilled and honoured to join @ard.eular.org as a guest Social Media Editor for #EULAR2025!🥳Thank you @alessiaalunno.bsky.social for the trust and support! Looking forward to sharing insights and highlights from this exciting congress. 🙌✨

Good morning Barcelona! We are fully operational onsite at #EULAR2025 with an enthusiastic team of guest Social Media Editors. 👉🏻Follow along for live updates!

Make the most of #EULAR2025 with the official Congress App! 🗺️ Navigate the 4-day event with ease, find session info, symposia, exhibition highlights, and venue services. 🗓️ Build your personal schedule 📱Download the EULAR 2025 Congress App and elevate your experience! #rheumatology

📢 Welcome to the ARD BlueSky Channel! 👉🏻 Follow along for the latest updates on published articles and more! 🎤 Stay tuned also for live coverage from #EULAR2025 Congress taking place in Barcelona on 11-14 June 2025. 📖 Browse the journal at www.sciencedirect.com/journal/anna...

🎙️ New EMEUNET #Podcast! ✨ RheumaVision 2025 Explained 🎥 How was #RheumaVision created? What's coming at #EULAR2025? 🚀 Join Renske, @jgletarouilly.bsky.social @TueKragstrup & me for a behind-the-scenes look! 🎧 Listen here 👉 open.spotify.com/episode/1TFg7j…

Look forward to chairing with you this exciting final of #RheumaVision! Our 6 finalists will present their topics to a prestigious jury: Denis Poddubnyy, Jette Primdahl, Caroline Ospelt and Simon Stones. Audience vote will be essential so join us! 🎉

We’re proud to reveal the #RheumaVision 2025 FINALISTS! 🎉 Brilliant early career rheumatologists sharing science through storytelling 🎥✨ Catch them at the Grand Finale during #EULAR2025 in Barcelona 🇪🇸 @jgletarouilly.bsky.social @eular.org @emeunet